National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

RFT5-dgA immunotoxin
A recombinant immunotoxin consisting of the anti-CD25 monoclonal antibody RFT5 fused to the deglycosylated ricin A-chain (dgA) with potential antitumor activity. The monoclonal antibody moiety of RFT5-dgA immunotoxin attaches to CD25 (the alpha chain of the IL-2 receptor complex) on the cell membrane; after internalization, the dgA moiety cleaves the N-glycosidic bond between the ribose and adenine base at position 4324 in 28S ribosomal RNA, resulting in ribosome inactivation, inhibition of protein synthesis, and cell death. CD25 is expressed on activated normal T and B cells and macrophages and is frequently upregulated in many hematologic malignancies. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-CD25 immunotoxin IMTOX25
Abbreviation:IgG-RFT5-dgA



Previous:Revlimid, RevM10 gene, REXIN-G, rexinoid NRX194204, Rezulin
Next:rhEndostatin, rhizoxin, ribavirin, riboflavin, ribosome-inactivating protein CY503

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov